Type 1 Diabetes

Researchers achieved successful reactivation of pancreatic stem cells to become insulin expressing, suggesting future potential for replacing destroyed beta cells in patients with type 1 diabetes with newborn insulin-generating cells.

More efforts need to be made to remove unconscious bias when implementing approved diabetes technologies into clinical practice for all patients, said Viral Shah, MD, an endocrinologist and scientist.

The National Health Service (NHS) in England has made the Dexcom ONE real-time Continuous Glucose Monitoring System available by prescription to patients with type 1 diabetes (T1D).

Compared with sensor-augmented pump therapy, closed-loop insulin delivery increased glucose time in range and reduced hypoglycemia episodes but detracted from sleep quality.

While therapies for type 1 diabetes (T1D) are becoming more advanced, the problem is patients can't access them, said Viral Shah, MD, an endocrinologist and scientist.

Viral Shah, MD, an endocrinologist and scientist, discusses ongoing research on preventing bone fractures in people with type 1 diabetes (T1D).

Probability of continuous glucose monitoring device use was highest for patients with type 1 diabetes (T1D) in middle adulthood, decreasing as older age increased.

Viral Shah, MD, an endocrinologist and scientist, discusses his research on fracture risk assessment without bone mineral density as a predictor of major fractures in patients with type 1 diabetes (T1D).

Current guidelines recommend screening for the 2 most commonly diagnosed autoimmune diseases among adolescent patients with type 1 diabetes, but researchers suggest that additional screenings could benefit patients.

Screening for islet autoantibodies at ages 2 and 6 was highly predictive of type 1 diabetes (T1D) onset by age 15.

Patients, parents, and diabetes health care providers all play a role in ensuring children with type 1 diabetes (T1D) get adequate sleep, said Stacey Simon, PhD, sleep psychologist and associate professor, University of Colorado Denver, Children's Hospital Colorado.

Although the autoimmune response that reduces β cell numbers has often been the focus of research in type 1 diabetes (T1D), findings from a new study suggest proinflammatory signaling in islet β cells may play a significant role in disease progression.

Viral Shah, MD, an endocrinologist and scientist, discusses the growing field of research into the connections between type 1 diabetes (T1D) and osteoporosis.

The Diabetes-Specific Risk-Taking Inventory proved useful in assessing risk-taking behavior in adolescents with type 1 diabetes (T1D), but future research on potential interventions is needed.

Research supports markers like C-peptide not only for the diagnosis of type 1 diabetes (T1D), but also for patient management.

Despite the increased prevalence of insulin pump use over the past 2 decades, there have been few improvements in uptake of the devices among patients who are Black or who come from lower socioeconomic levels.

Findings of a study on children and adolescents with type 1 diabetes (T1D) in Italy suggest lockdown periods during COVID-19 did not increase disordered eating symptoms or adversely affect disease management.

Patients said they benefited from diabetes management technology, but also from social accountability.

Body mass index did not appear to correlate with glycemic control, the study found.

The study suggests blood pressure and cholesterol medications may be appropriate for some younger patients in order to prevent renal complications.

The findings could lead to new insights into how type 1 diabetes develops.

In some cases, however, the rate of decline is no different than that of the general population, according to new research.

All patients said insulin pump therapy helped their diabetes management related to exercise.

The group noted that this transformation should affect changes at every level, including at the individual level during patient visits, at the organization level in how clinical encounters are organized, and at the national level in both policies and guidelines for type 1 diabetes (T1D).

The new findings come from a 15-year study examining the natural course of C-peptide in children and adolescents with type 1 diabetes (T1D).